Evidence map›Paper›PMID 40105194›Full record

ArticleEuropean journal of clinical investigation2025

Impact of sirolimus on long-term adverse cardiovascular outcomes in kidney transplant recipients: A nationwide cohort study.

Jinhyun Park, Wonhui Choi, Jinseub Hwang, Ha Young Jang, Yun Kim, Young-Mi Ah, Jin-Won Kwon, Kyung Hee Choi, Yun-Kyoung Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jinhyun ParkCollege of Pharmacy, Daegu Catholic University, Gyeongsan, Korea.
Wonhui ChoiDepartment of Statistics, Daegu University, Gyeongsan, Korea.
Jinseub HwangDepartment of Statistics, Daegu University, Gyeongsan, Korea.
Ha Young JangCollege of Pharmacy, Gachon University, Incheon, Korea.
Yun KimCollege of Pharmacy, Daegu Catholic University, Gyeongsan, Korea.
Young-Mi AhCollege of Pharmacy, Yeungnam University, Gyeongsan, Korea.
Jin-Won KwonBK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Korea.
Kyung Hee ChoiCollege of Pharmacy, Gachon University, Incheon, Korea.
Yun-Kyoung SongCollege of Pharmacy, The Catholic University of Korea, Bucheon, Korea.ORCID https://orcid.org/0000-0003-3687-4052

Funding

Ministry of Education NRF-2022R1C1C1011730
6 · The paper itself

Abstract

backgroundKidney transplant recipients (KTRs) are at high risk for cardiovascular disease due to the long-term use of immunosuppressive therapy. This study aims to evaluate the long-term impact of sirolimus on cardiovascular outcomes in Korean KTRs.

methodsFrom a cohort of 7180 eligible KTRs identified from 2010 to 2021, 387 KTRs who received sirolimus were included. To control for confounding variables, propensity score matching was applied, and the landmark method was used to address immortal time bias. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of myocardial infarction, coronary revascularization, ischaemic stroke and all-cause mortality.

resultsThe analysis showed no significant difference in MACE between the sirolimus-treated and untreated groups (hazard ratio, 1.40; 95% confidence interval, .77-2.55), despite a higher incidence of dyslipidaemia in the sirolimus-treated group. However, subgroup analysis revealed an increased MACE risk in KTRs with pre-transplant congestive heart failure (CHF) who were treated with sirolimus (hazard ratio, 6.22; 95% confidence interval, 1.78-21.74), while no significant differences were found in other subgroups.

conclusionsThese findings suggest that while sirolimus can be a viable option for immunosuppression, it should be used cautiously in those with pre-existing CHF.

Indexed as

Cardiovascular DiseasesImmunosuppressive AgentsKidney TransplantationSirolimusAdultAgedCause of DeathCohort StudiesDyslipidemiasFemaleGraft RejectionHeart FailureHumansIschemic StrokeMaleMiddle AgedImmunosuppressive AgentsSirolimusadverse cardiovascular outcomeskidney transplantationmTOR inhibitorsSirolimus

Identifiers

PMID40105194
PMCPMC12169092

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.